Trial Profile
Therapeutic multicentric phase II trial evaluating the efficacy of omalizumab (Xolair) in idiopathic refractory severe solar urticaria
Status:
Recruiting
Phase of Trial:
Phase II
Latest Information Update: 15 Sep 2015
Price :
$35
*
At a glance
- Drugs Omalizumab (Primary)
- Indications Urticaria
- Focus Therapeutic Use
- Acronyms XOLUS
- 15 Sep 2015 New trial record